Moors & Cabot Inc. Raises Position in Qiagen N.V. $QGEN

Moors & Cabot Inc. lifted its stake in Qiagen N.V. (NYSE:QGEN) by 78.2% in the 3rd quarter, HoldingsChannel reports. The firm owned 352,809 shares of the company’s stock after acquiring an additional 154,851 shares during the period. Qiagen makes up 0.7% of Moors & Cabot Inc.’s portfolio, making the stock its 29th largest holding. Moors & Cabot Inc.’s holdings in Qiagen were worth $15,764,000 as of its most recent SEC filing.

A number of other institutional investors also recently bought and sold shares of the stock. Johnson Investment Counsel Inc. grew its holdings in Qiagen by 0.4% during the third quarter. Johnson Investment Counsel Inc. now owns 57,359 shares of the company’s stock valued at $2,563,000 after purchasing an additional 240 shares during the period. Bessemer Group Inc. increased its position in Qiagen by 0.5% in the third quarter. Bessemer Group Inc. now owns 51,780 shares of the company’s stock worth $2,288,000 after buying an additional 262 shares in the last quarter. Covestor Ltd raised its stake in shares of Qiagen by 13.6% in the third quarter. Covestor Ltd now owns 3,007 shares of the company’s stock worth $134,000 after buying an additional 361 shares during the period. Private Advisor Group LLC lifted its position in shares of Qiagen by 7.1% during the 3rd quarter. Private Advisor Group LLC now owns 5,730 shares of the company’s stock valued at $256,000 after buying an additional 378 shares in the last quarter. Finally, PNC Financial Services Group Inc. grew its stake in shares of Qiagen by 4.5% during the 2nd quarter. PNC Financial Services Group Inc. now owns 9,672 shares of the company’s stock valued at $465,000 after acquiring an additional 415 shares during the period. 70.00% of the stock is owned by institutional investors.

Qiagen Price Performance

Shares of NYSE:QGEN opened at $40.91 on Tuesday. The firm has a market cap of $8.64 billion, a price-to-earnings ratio of 20.29, a P/E/G ratio of 1.98 and a beta of 0.70. Qiagen N.V. has a fifty-two week low of $40.14 and a fifty-two week high of $57.81. The company has a debt-to-equity ratio of 0.44, a quick ratio of 3.31 and a current ratio of 3.90. The firm has a fifty day moving average price of $49.15 and a 200 day moving average price of $48.78.

Qiagen (NYSE:QGEN) last issued its quarterly earnings data on Thursday, February 5th. The company reported $0.62 earnings per share for the quarter, beating analysts’ consensus estimates of $0.61 by $0.01. Qiagen had a return on equity of 14.56% and a net margin of 20.33%.The firm had revenue of $540.42 million during the quarter, compared to analyst estimates of $528.53 million. During the same quarter last year, the business posted $0.61 earnings per share. The business’s quarterly revenue was up 3.6% compared to the same quarter last year. As a group, sell-side analysts expect that Qiagen N.V. will post 2.26 earnings per share for the current fiscal year.

Analyst Ratings Changes

QGEN has been the subject of several analyst reports. Zacks Research lowered shares of Qiagen from a “hold” rating to a “strong sell” rating in a report on Monday, March 9th. Robert W. Baird set a $53.00 price objective on shares of Qiagen in a research report on Friday, February 6th. Weiss Ratings reaffirmed a “hold (c)” rating on shares of Qiagen in a report on Monday, December 29th. Deutsche Bank Aktiengesellschaft raised Qiagen from a “hold” rating to a “buy” rating and set a $54.00 price target on the stock in a report on Friday. Finally, JPMorgan Chase & Co. increased their target price on Qiagen from $55.00 to $60.00 and gave the stock an “overweight” rating in a research report on Friday, February 6th. Five investment analysts have rated the stock with a Buy rating, seven have issued a Hold rating and one has issued a Sell rating to the stock. According to data from MarketBeat, the company presently has a consensus rating of “Hold” and a consensus price target of $55.20.

Qiagen Company Profile

Qiagen NV (NYSE: QGEN) is a global provider of sample and assay technologies designed to enable molecular testing in the fields of molecular diagnostics, applied testing, academic research and pharmaceutical development. The company’s solutions span the full workflow of nucleic acid and protein analysis, offering customers standardized kits, instruments and software tools that streamline the preparation, detection and quantification of DNA, RNA and proteins.

The company’s product portfolio includes nucleic acid extraction and purification systems, polymerase chain reaction (PCR) reagents and instrumentation, digital PCR platforms, next-generation sequencing (NGS) library‐preparation kits and proteomics solutions.